Gary Nachman

Jay Olson

Jessica Fye

Yanan Zhu

Luca Issi

David Lebowitz

Michael Ulz

Yaron Werber

Akash Tewari

Andy Chen

Chi Meng Fong

Jason Gerberry

Mike Ulz

Mitchell Kapoor

Myles Minter

Avi Nova

Cassie Chen

Debjit Chattopadhyay

Gena Huidong Wang

Gena Wang

Gina Wang

Jacob Roberge

Jason Gerbery

Jeroen Werber

Lily Young

Mani Foroohar

Steven Eynav

Zaki Molvi

- IONIS reported **Q3 2025 revenues of $157 million**, comprising **$116 million** in commercial revenue and **$41 million** in R&D revenue, resulting in an **operating loss of ($129 million)**.  **[0000874015_2212045:11]** 
- **TRYNGOLZA** (olezarsen) injection, the company's first independent launch, generated **$32 million** in net sales in Q3 2025.  **[0000874015_2212045:3]** **[0000874015_2212045:11]** 
- The second independent launch, **DAWNZERA** (donidalorsen), is underway in the U.S. following FDA approval on August 21st, with a peak sales potential of **>$500 million**.  **[0000874015_2212045:3]** **[0000874015_2212045:10]** 
- The company reported positive Phase 3 data for **Olezarsen** in sHTG, demonstrating a **72%** placebo-adjusted mean reduction in fasting triglycerides and an **85%** reduction in acute pancreatitis events, with SNDA submission on track by year-end 2025.  **[0000874015_2212045:3]** **[0000874015_2212045:4]** **[0000874015_2212045:5]** **[0000874015_2212045:6]**

IONIS Reports Q3 2025 Financial Results and Provides Product Updates

- Ionis reported **Q3 2025 revenue of $157 million**, a **17% increase year-over-year**, and **$740 million** for the first nine months, representing a **55% increase** compared with the prior year.  **[0000874015_2214378_6]** 
- The company raised its **2025 financial guidance**, now expecting total revenue between **$875 million and $900 million** and TRYNGOLZA product sales between **$85 million and $95 million** for the full year.  **[0000874015_2214378_6]** 
- **TRYNGOLZA** product sales reached **$32 million** in Q3 2025, a **nearly 70% increase quarter over quarter**, and **DAWNZERA** received FDA approval in August, marking Ionis's second independent launch.  **[0000874015_2214378_1]** **[0000874015_2214378_4]** **[0000874015_2214378_6]** 
- Ionis announced positive Phase III results for **olzarsen** in severe hypertriglyceridemia (showing up to **72% reduction in triglycerides** and **85% reduction in acute pancreatitis events**) and for **zilganersen** in Alexander disease (showing a **33% mean benefit in gait speed**), with anticipated launches next year.  **[0000874015_2214378_1]** **[0000874015_2214378_2]**  Peak sales expectations are **greater than $1 billion** for olzarsen, **greater than $500 million** for DAWNZERA, and **greater than $100 million** for zilganersen.  **[0000874015_2214378_8]** **[0000874015_2214378_14]**  The company targets cash flow breakeven by **2028**.  **[0000874015_2214378_6]** **[0000874015_2214378_7]**

Ionis Reports Strong Q3 2025 Results, Raises Full-Year Guidance, and Prepares for New Product Launches

- Ionis Pharmaceuticals reported **$157 million** in revenue for Q3 2025, representing a **17% increase** year over year, with revenue for the first nine months of 2025 totaling **$740 million**, an increase of **55%** compared to the prior year.  **[0000874015_2211884_6]** 
- The company raised its 2025 financial guidance, now expecting total revenue between **$875 million and $900 million** and Tringolsa product sales between **$85 million and $95 million** for the full year.  **[0000874015_2211884_6]** 
- Tringolsa product sales reached **$32 million** in Q3 2025, reflecting a nearly **70% increase** quarter over quarter, while Donzera, approved in August 2025, is anticipated to provide a modest revenue contribution this year.  **[0000874015_2211884_4]** **[0000874015_2211884_6]** 
- Positive Phase 3 results for Olzarsen and Zilganersen are paving the way for two additional independent launches next year, with Olzarsen projected to achieve **greater than $1 billion** in peak sales and Zilganersen **greater than $100 million**.  **[0000874015_2211884_1]** **[0000874015_2211884_2]** **[0000874015_2211884_8]** 
- Ionis expects to end 2025 with a cash balance of **more than $2.1 billion** and aims to achieve cash flow breakeven by **2028**.  **[0000874015_2211884_6]** **[0000874015_2211884_7]**

Ionis Pharmaceuticals Reports Strong Q3 2025 Results and Raises Full-Year Guidance

- Ionis reported **Q3 2025 revenue of $157 million**, a **17% increase** year-over-year, and **year-to-date revenue of $740 million**, up **55%** compared to the prior year.  **[0000874015_2213917_6]** 
- The company raised its **2025 financial guidance**, now expecting total revenue between **$875 million and $900 million** and Tringolsa product sales between **$85 million and $95 million** for the full year.  **[0000874015_2213917_6]** 
- **Tringolsa** (for FCS) continued its strong launch momentum with **$32 million** in Q3 product sales, a **70% increase** quarter-over-quarter, and **Donzera** (for HAE) was FDA-approved in August, marking its second independent launch.  **[0000874015_2213917_1]** **[0000874015_2213917_4]** **[0000874015_2213917_6]**  Donzera is expected to achieve peak sales greater than **$500 million**.  **[0000874015_2213917_8]** 
- Positive Phase 3 results for **Olzarsen** (for SHTG) and **Zilganersen** (for Alexander disease) position them for independent launches next year, with Olzarsen projected for peak sales greater than **$1 billion** and Zilganersen greater than **$100 million**.  **[0000874015_2213917_1]** **[0000874015_2213917_2]** **[0000874015_2213917_8]**

Ionis Reports Strong Q3 2025 Results and Raises Full-Year Guidance

- Ionis Pharmaceuticals reported **total revenue of $157 million** and a **net loss of $(129) million**, or **$(0.80) per share**, for the third quarter ended September 30, 2025.  **[874015_0001140361-25-039650_ef20057869_ex99-1.htm:0]** **[874015_0001140361-25-039650_ef20057869_ex99-1.htm:5]** 
- The company **increased its 2025 financial guidance**, with new total revenue guidance of **$875-900 million** and TRYNGOLZA product sales guidance of **$85-95 million**.  **[874015_0001140361-25-039650_ef20057869_ex99-1.htm:0]** 
- **TRYNGOLZA® generated $32 million in net product sales** in Q3 2025, marking a nearly **70% increase over the prior quarter**, and the **DAWNZERA™ launch is off to an encouraging start** following its FDA approval on August 21, 2025.  **[874015_0001140361-25-039650_ef20057869_ex99-1.htm:0]** **[874015_0001140361-25-039650_ef20057869_ex99-1.htm:1]** 
- Ionis announced **positive topline Phase 3 results for olezarsen** in severe hypertriglyceridemia, with an sNDA submission planned by year-end 2025, and **positive pivotal results for zilganersen** in Alexander disease, with an NDA submission planned for Q1 2026.  **[874015_0001140361-25-039650_ef20057869_ex99-1.htm:0]** **[874015_0001140361-25-039650_ef20057869_ex99-1.htm:1]**

Ionis Pharmaceuticals Announces Strong Q3 2025 Results and Increased 2025 Guidance

- Ionis Pharmaceuticals reported **total revenue of $157 million** for the third quarter of 2025, an increase of 17% compared to the same period last year.  **[874015_fc00e1d48df94a5693490146977ec7e3_0]** **[874015_fc00e1d48df94a5693490146977ec7e3_1]** 
- **TRYNGOLZA net product sales generated $32 million** in the third quarter of 2025, representing a nearly 70% increase over the prior quarter.  **[874015_fc00e1d48df94a5693490146977ec7e3_0]** **[874015_fc00e1d48df94a5693490146977ec7e3_2]** 
- The company **increased its full-year 2025 financial guidance**, with new total revenue guidance of **$875-900 million** and non-GAAP operating loss guidance of **$275-300 million**.  **[874015_fc00e1d48df94a5693490146977ec7e3_1]** 
- **DAWNZERA** (donidalorsen) received FDA approval on August 21, 2025, and its U.S. launch is off to an encouraging start.  **[874015_fc00e1d48df94a5693490146977ec7e3_2]** 
- Positive pivotal Phase 3 results were announced for **olezarsen** in severe hypertriglyceridemia and **zilganersen** in Alexander disease, with regulatory filings planned in the coming months.  **[874015_fc00e1d48df94a5693490146977ec7e3_0]** **[874015_fc00e1d48df94a5693490146977ec7e3_2]**

Ionis Reports Strong Q3 2025 Financial Results and Raises Full-Year Guidance

- Ionis Pharmaceuticals reported **third-quarter revenue of $157 million** and narrowed its loss per share to **$0.80**, both exceeding market expectations.  **[874015_c786ff568ed7468cb1eb5ed3571f60b1]** 
- The company **raised its full-year 2025 revenue guidance to $875–900 million** from $825–850 million, primarily due to strong product sales and a **$280 million upfront payment** from a licensing deal.  **[874015_c786ff568ed7468cb1eb5ed3571f60b1]** 
- Ionis is advancing its drug pipeline with promising Phase 3 trial results and plans regulatory submissions soon, while maintaining a **strong financial position** with a current ratio of **2.87** and a quick ratio of **2.86**.  **[874015_c786ff568ed7468cb1eb5ed3571f60b1]**

Ionis Pharmaceuticals Raises 2025 Revenue Guidance After Strong Q3 Performance

- Ionis Pharmaceuticals announced that **detailed data** from its Phase 3 CORE and CORE2 studies of **olezarsen** for severe hypertriglyceridemia (sHTG) will be presented at the American Heart Association (AHA) Scientific Sessions on **November 8**.  **[874015_3fe67bccfefc488a83888557c0fd140a_0]** 
- The company previously reported **positive topline results** from these studies, demonstrating a statistically significant reduction in fasting triglycerides and acute pancreatitis events.  **[874015_3fe67bccfefc488a83888557c0fd140a_0]** 
- Ionis plans to submit a supplemental new drug application for olezarsen to the U.S. FDA by the **end of the year**.  **[874015_3fe67bccfefc488a83888557c0fd140a_0]** 
- Ionis will host a **webcast** on **November 8 at 3:00 p.m. ET** to discuss the CORE and CORE2 study results.  **[874015_3fe67bccfefc488a83888557c0fd140a_0]**

Ionis Pharmaceuticals to Present Detailed Olezarsen Study Data at AHA Scientific Sessions

- The Complement 3 Glomerulopathy (C3G) market is projected to expand significantly, with a **CAGR of 37.2%** during the **2025–2034** forecast period, and is expected to reach **USD 1 Billion by 2034**.  **[874015_296231e75d9448fda5c850a928170e3e_0]** **[874015_296231e75d9448fda5c850a928170e3e_4]** 
- In **2024**, the market size for C3G in leading markets was **USD 36 million**, with the United States representing approximately **73%** of this total.  **[874015_296231e75d9448fda5c850a928170e3e_0]** 
- Key companies such as **Kira Pharmaceuticals, Omeros Corporation, NovelMed Therapeutics, and Arrowhead Pharmaceuticals** are actively developing pipeline therapies, including **KP104, Zaltenibart, Ruxoprubart, and ARO-C3**.  **[874015_296231e75d9448fda5c850a928170e3e_0]** **[874015_296231e75d9448fda5c850a928170e3e_2]** **[874015_296231e75d9448fda5c850a928170e3e_4]** 
- Recent regulatory approvals for C3G treatment include **pegcetacoplan** by the FDA in **July 2025** and **iptacopan** by the US FDA in **March 2025**, which also received a positive EMA CHMP opinion in **April 2025**.  **[874015_296231e75d9448fda5c850a928170e3e_3]**

IONS: Complement 3 Glomerulopathy Market Forecasted for Substantial Growth

- Ionis Pharmaceuticals has received multiple positive analyst ratings upgrades, including **JP Morgan's upgrade from Neutral to Overweight** and a price target increase from $49 to **$80**.  **[874015_9d6c233df62d49ff8c1993703d79c5f7]** 
- The company's financial health is strong, with a projected **$2.0 billion cash balance** and anticipated **cash flow positivity by 2028**.  **[874015_9d6c233df62d49ff8c1993703d79c5f7]** 
- Analysts highlight the expanded commercial potential of Ionis's drug olezarsen, which is now projected to reach **$1 billion by 2033** due to its potential use in severe hypertriglyceridemia.  **[874015_9d6c233df62d49ff8c1993703d79c5f7]** 
- Despite a **170% year-to-date rally**, JP Morgan's new price target of **$80** suggests further appreciation, being approximately **16% above** the stock’s closing price at the time.  **[874015_9d6c233df62d49ff8c1993703d79c5f7]**

IONIS PHARMACEUTICALS (IONS)